Valuation: Verastem, Inc.

Market Cap 486M 425M 392M 362M 687M 46.35B 699M 4.68B 1.84B 22.83B 1.82B 1.78B 78.49B P/E 2026 *
-3.49x
P/E 2027 * -4.93x
Enterprise Value 321M 281M 259M 239M 454M 30.61B 461M 3.09B 1.21B 15.08B 1.21B 1.18B 51.84B EV / Sales 2026 *
3.15x
EV / Sales 2027 * 1.55x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day+2.41%
1 week+22.89%
Current month+44.76%
1 month+40.36%
3 months+4.14%
6 months-29.01%
Current year-28.37%
1 week 4.3
Extreme 4.3
5.57
1 month 3.43
Extreme 3.43
5.57
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
45.6
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 31/07/2023
Director of Finance/CFO 39 30/10/2022
Chief Tech/Sci/R&D Officer - 17/04/2024
Director TitleAgeSince
Director/Board Member 60 25/05/2026
Director/Board Member 69 02/05/2017
Chairman 68 14/12/2025
Date Insider Type Main position Quantity % Market Cap.
06-21Sell

Chief Executive Officer

-20,871 0.0339%
06-21Sell

Chief Financial Officer

-4,089 0.0066%
05-20Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
+2.41%+22.89%+18.04%-39.63% 486M
-4.14%-8.06%+58.96%+118.67% 54.63B
+1.84%-0.66%+59.82%+92.96% 54.88B
-2.24%+3.59%+17.75%+477.47% 25.06B
-1.60%-6.21%-18.96%-15.21% 23.14B
+2.43%+1.06%+42.44%-1.27% 19.88B
-3.19%0.00%+35.60%-26.98% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
-1.05%+1.16%+25.95%+194.27% 14.2B
+8.74%+3.51%+51.91%+726.40% 15.36B
Average -0.36%+2.04%+48.66%+188.38% 24.17B
Weighted average by Cap. -0.90%-1.41%+51.20%+175.82%

Financials

2026 *2027 *
Net sales 102M 89.11M 82.19M 75.91M 144M 9.72B 146M 982M 386M 4.79B 382M 374M 16.45B 178M 156M 144M 133M 252M 17.01B 256M 1.72B 675M 8.38B 670M 655M 28.81B
Net income -167M -146M -134M -124M -235M -15.89B -239M -1.61B -631M -7.83B -625M -612M -26.9B -142M -124M -115M -106M -201M -13.55B -204M -1.37B -538M -6.67B -533M -522M -22.95B
Net Debt -165M -144M -133M -123M -233M -15.74B -237M -1.59B -625M -7.75B -620M -606M -26.65B -210M -183M -169M -156M -296M -19.99B -301M -2.02B -793M -9.85B -787M -770M -33.86B
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
10/07/26 US$5.530 +2.41% 2,989,325
09/07/26 US$5.400 +6.30% 5,131,391
08/07/26 US$5.080 +4.74% 4,355,021
07/07/26 US$4.850 +8.74% 2,851,784
06/07/26 US$4.460 -0.89% 1,811,512
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.530USD
Average target price
15.00USD
Spread / Average Target
+171.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock